Log in to search using one of your social media accounts:

 

Medical News Today: Hormone replacement therapy may increase risk of hearing loss

A new, first-of-its-kind study investigates the link between hormone replacement therapy and hearing loss in menopausal and postmenopausal women.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Hearing / Deafness Source Type: news

Related Links:

ConclusionsThis case series assessment found a suggestive causal relationship between hydrochlorothiazide and hearing disorder. Taking the inherent limitations of this study into account, results should be interpreted with caution and further studies are required to validate the safety signal.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Authors: Nakamura S, Tsujioka H, Fukami T, Goto M, Matsuoka R, Eguchi F Abstract The authors here report a 54-year-old (gravida 0, para 0), who claimed to have had her menarche at age 13 and menopause at 52 years. Two months prior to presentation, the subject first noticed a hard but elastic fist-sized mass in the left inguinal region that gradually grew, causing pressure-related pain. Although the external genitalia appeared female, the vagina was short and blind-ending, and no uterus or ovaries were identified on transvaginal ultrasound. Chromosome banding results (G-band method) showed 46XY. Laparoscopy revealed...
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSION: In this study; the age of> 50 years was detected as an independent factor for having at least borderline pathology for adnexal masses. The data from these results might be used as a differential diagnostic tool in a new combination for benign and malignant adnexal masses in future studies. PMID: 29767874 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
On Thursday, the Food and Drug Administration approved the first drug designed to prevent chronic migraine headaches. Aimovig, made by Amgen and Novartis, is a monthly, self-administered injection that blocks a molecule involved in migraine attacks. Over the course of three clinical trials, the drug was successful at reducing the frequency of migraines for chronic sufferers. It is expected to be available in as soon as a week and will cost $575 per month, though out-of-pocket costs will vary depending on insurance. This is the story of Susan Giordano, 58, whose chronic migraines have nearly ceased after taking a monthly s...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime medicine onetime Source Type: news
Conditions:   Hypertension;   Menopause Intervention:   Other: Combined exercise Sponsor:   Federal University of Uberlandia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Pelzer ES, Willner D, Buttini M, Hafner LM, Theodoropoulos C, Huygens F Abstract Objective: There is a paucity of data characterizing the microbiota of the female upper genital tract, which controversially is described as a sterile site. We examine whether the fallopian tube harbours an endogenous microbial community. Design: This prospective study collected from women undergoing total hysterectomy or salpingectomy-oophorectomy. Setting: Private hospital gynaecology department. Patients: Fallopian tubes were collected from women diagnosed with benign disease or for prophylaxis. Intervention...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Horakova D, Bouchalova K, Cwiertka K, Stepanek L, Vlckova J, Kollarova H Abstract Triple negative breast cancer (TNBC) is an aggressive form of breast cancer (BC) with a poor prognosis. Second, patients cannot benefit from targeted therapy, except for those with BRCA1/2 mutations, for whom poly (ADP-ribose) polymerase (PARP) inhibition therapy using olaparib has recently been approved. As global priorities continue to be epidemiological analysis of BC risk factors and early diagnosis, this review focuses on the risks and protective factors associated with TNBC. A PubMed keyword search for new knowledge on ...
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research
WARNING: GRAPHIC CONTENT Stomach-churning footage from UK audiologist Neel Raithatha shows a woman who was left deaf by a huge chunk of ear wax finally having it removed.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Older age at menopause also appeared to increase the risk, study found Source: HealthDay Related MedlinePlus Pages: Hearing Disorders and Deafness, Hormone Replacement Therapy, Menopause
Source: MedlinePlus Health News - Category: Consumer Health News Source Type: news
More News: Audiology | Deafness | Health | Hormone Replacement Therapy | Hormones | Men | Menopause | Study | Women